SD HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
A San Diego-based immunotherapy company has successfully completed $100,000 of financing by utilizing an unusual fundraising approach — crowd funding.
Sanford-Burnham Medical Research Institute’s board of trustees has appointed Perry Nisen as CEO and holder of the Donald Bren chief executive chair for the institute’s La Jolla-based headquarters.
San Diego-based Cytori Therapeutics Inc. announced that Tiago Girão has been appointed vice president and chief financial officer.
ResMed Inc. has released its new sleep apnea therapy device that will use patient data and communication software to help health care providers monitor and analyze their patients’ conditions.
BIOTECH: FDA Grants Orphan Drug Status to Promising New Therapy
Mirati Therapeutics Inc., a public company in San Diego developing medicines for targeted oncology, is one step closer to achieving regulatory approval for its cancer drug Mocetinostat.
Ligand Pharmaceuticals Inc. announced the signing of a commercial license agreement with Atlanta, Georgia-based Avion Pharmaceuticals LLC for the development and commercialization of four Captisol-enabled programs
The Defense Department said on Aug. 14 that it awarded a $9.1 million contract modification to Thermo Fisher Scientific to acquire reagents and consumables for its DNA Identification Laboratory at the Armed Forces Medical Examiners System at Dover Air Force Base in Delaware.
Shares of Otonomy Inc. were rising Aug. 13 after the biotech drug developer's initial public offering raised $100 million.
Cytori Therapeutics Inc. reported a net loss of $11.8 million for second quarter 2014, down from a net loss $3.2 million during the same period in 2013.
The opening of the 23,000-square-foot medical office building was celebrated with a public event.
The Scripps Research Institute appointed James Paulson, chair of its Department of Cell and Molecular Biology, as acting president and CEO, the institute’s board of trustees announced Monday.
San Diego-based Ligand Pharmaceuticals Inc. announced that it intends to offer $225 million of convertible senior notes due 2019 and has authorized a $200 million share repurchase program over the next 12 months.
San Diego-based cancer drug developer Ignyta Inc. has appointed Adrian Senderowicz as chief medical officer and senior vice president of clinical development and regulatory affairs.
ViaCyte Inc. has announced it has raised $5.4 million in private financing to pursue the clinical development of its artificial pancreas, which could treat type 1 diabetes.